Response to Letter Regarding Article, “CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China”
Meijuan Zhang,Yun Xu
DOI: https://doi.org/10.1161/strokeaha.113.002158
IF: 10.17
2013-01-01
Stroke
Abstract:HomeStrokeVol. 44, No. 9Response to Letter Regarding Article, “CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBResponse to Letter Regarding Article, “CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China” Meijuan Zhang, MD, PhD and Yun Xu, MD, PhD Meijuan ZhangMeijuan Zhang Department of Neurology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, PR China Search for more papers by this author and Yun XuYun Xu Department of Neurology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, PR China Search for more papers by this author Originally published13 Aug 2013https://doi.org/10.1161/STROKEAHA.113.002158Stroke. 2013;44:e108Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: January 1, 2013: Previous Version 1 We thank Jia et al for their valuable comments regarding our recently published article.1 This prospective study enrolled 259 patients with acute ischemic stroke and found that CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) genotypes had significant impact on clopidogrel response and prognosis of patients with stroke.We have to clarify that the National Institutes of Health Stroke Scale and modified Rankin Scale score in our study were used to evaluate the therapeutic effect of clopidogrel at 3 and 6 months after treatment. In addition to coagulation, platelets also release abundant proinflammatory cytokines that aggravate the pathogenic progress of ischemic injury. Substantial evidence demonstrated that clopidogrel application diminished inflammatory mediators, including C-reactive protein.2 Meanwhile, clopidogrel was also reported to inhibit leukocyte infiltration and decrease the expression of chemotactic factors in inflammatory diseases.3 These results may reflect an early beneficial effect of clopidogrel in patients with stroke. In addition, the latest US guidelines for the early management of patients with acute ischemic stroke also accepted and presented data about beneficial effects of antiplatelet agents in acute stroke assessed by modified Rankin Scale.4 Thus, our data should not be interpreted in the way that CYP2C19 loss-of-function allele is associated with increased risk of recurrent stroke events. The role of clopidogrel polymorphisms in stroke recurrence is an interesting question which we have devoted much time to elicit in recent years. However, we have not ceased our follow-up for it calls for much longer time period than this study.Currently, it is widely accepted that CYP2C19 loss-of-function allele is a major determinant of clopidogrel responsiveness not only in patients with cardiovascular and cerebrovascular diseases, but also in healthy volunteers. However, there is no definitive evidence linking ex vivo platelet aggregation measurements to clinical outcome, and it is still unclear how patients should be managed based on these test results. One of the major problems is lack of confident parameters about activity of clopidogrel in vivo. Nowadays, several platelet function tests that measure the downstream response of clopidogrel on P2Y12 receptor are available, including light transmittance aggregometry, VerifyNow test, and vasodilator-stimulated phosphoprotein phosphorylation analysis.5 These platelet function tests ex vivo lack universal standards and sometimes hardly reflect the real response of clopidogrel in vivo. In our study, we used ADP-induced light transmittance aggregometry assay and found that there were no differences in the average uninhibited baseline platelet functional response to ADP between responders and nonresponders (data not shown). We also evaluated the association between platelet aggregation and stroke outcome, which showed that patients with high platelet aggregation reactivity had bad outcome (data not shown). However, the plasma levels of clopidogrel and its active metabolite in each genotype were not detected in our study. We initially provided evidence that CYP2C19 genotypes had substantial impact on the prognosis of patients with acute stroke when applying clopidogrel. Further studies devoted to establish reliable parameters of clopidogrel response in vivo and verify our findings in multicenter randomized and long-term trials may help develop clinical decisions based on CYP2C19 polymorphisms.Meijuan Zhang, MD, PhDYun Xu, MD, PhDDepartment of NeurologyDrum Tower HospitalNanjing University Medical SchoolNanjing, PR ChinaDisclosuresNone.FootnotesStroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. Letters must reference a Stroke published-ahead-of-print article or an article printed within the past 3 weeks. The maximum length is 750 words including no more than 5 references and 3 authors. Please submit letters typed double-spaced. Letters may be shortened or edited. References 1. Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, et al. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.Stroke. 2013; 44:1717–1719.LinkGoogle Scholar2. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Lüscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.Vasc Med. 2007; 12:113–122.CrossrefMedlineGoogle Scholar3. Liu O, Jia L, Liu X, Wang Y, Wang X, Qin Y, et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression.PLoS One. 2012; 7:e51707.CrossrefMedlineGoogle Scholar4. Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2013; 44:870–947.LinkGoogle Scholar5. Price MJ, Barker CM. Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.Biomark Med. 2011; 5:43–51.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails September 2013Vol 44, Issue 9 Advertisement Article InformationMetrics © 2013 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.113.002158PMID: 23943214 Originally publishedAugust 13, 2013 PDF download Advertisement SubjectsTreatment